Related Experiment Video
Updated: Jun 12, 2025
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
Unveiling the Potential of S4 on Non-small Cell Lung Cancer Cells: Impact on Proliferation, Apoptosis, Senescence,
Turan Demircan1, Mervenur Yavuz2, Aydın Boluk3
1Department of Medical Biology, School of Medicine, Muğla Sıtkı Koçman University, Muğla, Turkey.
Background:
Lung cancer is a highly aggressive tumor with limited therapeutic options. The misregulation of Androgen Receptor (AR) signaling has been observed in lung cancer. Therefore, inhibiting AR signaling is a promising strategy for treating lung cancer.
Objective:
Selective Androgen Receptor Modulators (SARMs) are small molecule drugs with a high affinity for the AR. S4, a member of SARMs was potentially positioned as a promising therapeutic agent in A549 lung cancer cells owing to its high bioavailability, lesser side effects, and novelty in cancer.
Methods:
We employed several techniques to investigate the potential anti-carcinogenic effect of S4 on A549 cells at cellular level. The cytotoxicity of S4 was investigated thorough MTT, and the IC50 value was identified as 0.22 mM. Then, the anchorage-dependent and -independent colonization of cells were assessed by colony formation and soft agar assays, respectively. Additionally, migration capacity, apoptosis, proliferation, senescene, cell-cycle progression of cells was examined thoroughly. In addition, gene expression profile and metabolome signature were explored via qRT-PCR and metabolomics, respectively to provide molecular links for S4 mode of action.
Results:
Our findings demonstrate that S4 inhibited growth, migration, and proliferation while inducing apoptosis. S4 significantly upregulated the BAX, CDKN1A, PUMA, and GADD45A genes while downregulating MKI67, BIRC5, and PCNA expression. S4 treatment drastically altered the metabolome signature, and enrichment of cancer related pathways by altered metabolites was noteworthy.
Conclusion:
We report the first study evaluating the potential anti-carcinogenic effects of S4 on lung cancer invitro which would bridge the gap on the utility of SARMs as inhibitors of lung cancer. Our results suggest that S4 could be considered as a promising drug candidate to test further for lung cancer treatment.
Insights
Selective Androgen Receptor Modulators (SARMs) show potential in treating lung cancer. S4 effectively inhibited cancer cell growth, migration, and proliferation while inducing apoptosis in vitro.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Lung cancer is an aggressive malignancy with limited treatment options.
- Androgen Receptor (AR) signaling is frequently misregulated in lung cancer, making AR inhibition a viable therapeutic strategy.
- Selective Androgen Receptor Modulators (SARMs) are novel small molecules with high AR affinity and potential therapeutic benefits.
Purpose of the Study:
- To investigate the anti-carcinogenic effects of S4, a SARM, on A549 lung cancer cells in vitro.
- To evaluate S4's efficacy in inhibiting cancer cell growth, migration, and proliferation.
- To explore the molecular mechanisms underlying S4's anti-cancer activity.
Main Methods:
- Cytotoxicity assessed via MTT assay to determine IC50 value.
- Colony formation and soft agar assays evaluated anchorage-dependent and -independent cell colonization.
- Apoptosis, proliferation, senescence, and cell-cycle progression were analyzed.
- Gene expression profiling (qRT-PCR) and metabolomics were employed to elucidate S4's mode of action.
Main Results:
- S4 demonstrated significant inhibition of lung cancer cell growth, migration, and proliferation.
- S4 induced apoptosis in A549 cells.
- Gene expression analysis revealed upregulation of pro-apoptotic genes (BAX, CDKN1A, PUMA, GADD45A) and downregulation of proliferation markers (MKI67, BIRC5, PCNA).
- Metabolomic profiling showed significant alterations in metabolic pathways relevant to cancer.
Conclusions:
- This study provides the first in vitro evaluation of S4's anti-cancer effects in lung cancer.
- S4 exhibits promising anti-carcinogenic properties, warranting further investigation as a potential therapeutic agent for lung cancer.
- SARMs represent a novel class of drugs with potential utility in inhibiting lung cancer progression.
